علاج ضخامة النهايات في الحمل: إدارة المريضة التي تخطط للإنجاب

References

DOI: 10.1210/jc.2014-2700

For the patient with acromegaly who becomes pregnant, there is a concern for a possible stimulatory effect of the pregnancy on somatotroph tumor size, the effects of GH excess on the mother, and the safety of medications used to treat acromegaly.

We suggest discontinuing long-acting SRL formulations and pegvisomant approximately 2 months before attempts to conceive, with use of short-acting octreotide as necessary until conception.